Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

$5.29 Billion Genome Editing Market Analysis and Leading Industry Players, 2026: Trends and Growth Forecast to 2035

globenewswire.com
ARCT Arcturus Therapeutics is mentioned as a company assessed in the genome editing market. The article provides a general market analysis and does not offer specific sentiment towards this company. BTAI Beam Therapeutics is listed as a company assessed in the genome editing market. The article focuses on market trends and growth, without specific sentiment for this company. CRSP CRISPR Therapeutics is mentioned as a company assessed in the genome editing market. The article discusses market drivers like CRISPR-Cas systems but doesn't provide specific sentiment for the company. EDIT Editas Medicine is listed as a company assessed in the genome editing market. The article provides a general market overview and growth forecast, not specific sentiment for this company. NTLA Intellia Therapeutics is named as a company evaluated within the genome editing market. The article focuses on market trends and growth, without specific sentiment for this company. VOR Vor Biopharma is listed as a company assessed in the genome editing market. The article focuses on market trends and growth, without specific sentiment for this company.

$5.29 Billion Genome Editing Market Analysis and Leading Industry Players, 2026: Trends and Growth Forecast to 2035 Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Genome Editing Market Analysis and Leading Industry Players - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering.

The global genome editing market is projected to increase from USD 5.29 billion in 2026 to USD 13.36 billion by 2035, expanding at a compound annual growth rate of 10.8%. Clinical validation of gene-edited therapies, growing technology licensing activity, and continued advances in CRISPR-Cas systems are expected to support market growth throughout the forecast period.

Genome Editing Market Growth and Industry Trends

CRISPR-Cas systems currently lead the genome editing technology landscape, supported by their precision, cost efficiency, versatility, and ease of design. Zinc finger nucleases, transcription activator-like effector nucleases, meganucleases, base editing, and prime editing also contribute to a rapidly evolving technology portfolio.

The commercial outlook for genome editing has strengthened as genetic disorders continue to create substantial unmet medical needs and regulatory pathways for cell and gene therapies mature. More than 1,000 active clinical programs are evaluating gene-based and gene-edited interventions, accelerating the transition of genome editing technologies from research applications to therapeutic development.

Pharmaceutical and biotechnology companies are increasingly licensing external genome editing platforms rather than developing proprietary technologies internally. High discovery costs, complex intellectual property considerations, and demanding regulatory requirements have created a growing technology-licensing economy. Upfront payments currently represent the largest share of licensing value, while milestone-based payments are projected to become the leading payment category by 2035 as clinical programs advance toward regulatory and commercial milestones.

Key Genome Editing Market Drivers

Market expansion is being driven by the clinical progress of CRISPR-based cell and gene therapies and the widening use of genome editing in oncology, neurology, metabolic disorders, diagnostics, agriculture, and drug discovery. Next-generation base and prime editing platforms are improving accuracy and reducing unwanted edits, creating opportunities across a broader range of therapeutic indications.

Drug discovery and development currently represent the leading application area, supported by CRISPR-based screening for target identification and validation. Diagnostic applications are expected to record faster growth as genome editing platforms are increasingly adapted for early and precise disease detection.

Market Challenges and Technology Barriers

In vivo genome editing continues to face challenges related to immunogenicity, tissue specificity, delivery efficiency, and off-target effects. Ex vivo approaches provide greater control over editing quality and safety but remain constrained by high manufacturing costs and operational complexity. Fragmented CRISPR intellectual property rights and evolving regulatory frameworks also create uncertainty for technology developers, licensees, investors, and commercialization partners.

Genome Editing Market Segmentation Highlights

Regional Genome Editing Market Outlook

North America holds the largest share of the global genome editing market and is expected to retain its leadership through 2035. The region benefits from a strong concentration of technology developers, substantial venture and institutional investment, extensive clinical research activity, and a high volume of licensing transactions.

Asia-Pacific is projected to expand at a higher CAGR, supported by growing biotechnology investment, research capabilities, clinical development activity, and government initiatives. The report evaluates opportunities across the United States, Canada, Germany, France, Ireland, China, Japan, South Korea, and other major markets.

Competitive Landscape

Companies assessed in the genome editing market include Arcturus Therapeutics, ArsenalBio, Avectas, Beam Therapeutics, Bio-Sourcing, Caribou Biosciences, Century Therapeutics, CRISPR Therapeutics, Editas Medicine, Flash BioSolutions, Graphite Bio, Intellia Therapeutics, NTrans Technologies, OXGENE, Prime Medicine, Revvity, and Vor Biopharma.

The competitive analysis examines company strength, technology portfolios, clinical development capabilities, partnerships, licensing agreements, funding activity, patent positions, and recent strategic developments. It also reviews collaborations announced since 2018 and identifies active technology providers, investors, and commercial partners across North America, Europe, and Asia-Pacific.

Genome Editing Market Report Coverage

The research provides market sizing and forecast analysis by payment method, gene editing technique, editing approach, delivery method, delivery modality, therapy type, application area, end user, and geography. It also includes technology benchmarking, developer profiles, partnership analysis, patent valuation, funding trends, competitive positioning, and an assessment of market drivers, restraints, challenges, and commercial opportunities.

Primary research incorporates perspectives from senior executives and scientific leaders at large and mid-sized organizations in the United States and Europe, as well as academic research stakeholders in Asia-Pacific. These insights support an evidence-based assessment of technology adoption, licensing structures, development priorities, and investment trends.

The report is designed to help pharmaceutical companies, biotechnology organizations, investors, distributors, licensees, and research institutions evaluate market opportunities through 2035. It addresses the changing balance between upfront and milestone payments, the technologies gaining market share, the strongest emerging applications, regional growth prospects, and the companies positioned to influence the future of the global genome editing market.

A selection of companies mentioned in this report includes, but is not limited to:

For more information about this report visit https://www.researchandmarkets.com/r/42uslx

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.